In September the US Food and Drug Administration issued an updated preliminary list of 91 new drug applications approved under the Food, Drug and Cosmetic Act that will become “deemed” biologics license applications regulated under the Public Health Service on 23 March 2020 when the Biologics Price Competition and Innovation Act’s transition provisions take effect. A Pink Sheet infographic shows how insulins account for the largest group of products affected by the transition and Pink Sheet shares details on the products in question by category including whether they were active or discontinued.